Rationale for surrogate testing to detect non-A, non-B hepatitis

Results of a hepatitis C general transfusion lookback program for patients who received blood products before July 1992

BACKGROUND

The Centers for Disease Control and Prevention recommend hepatitis C virus (HCV) antibody (anti-HCV) screening for persons who received blood products before July 1992. A general transfusion lookback program was implemented to identify, counsel, and screen persons who received transfusions at the Alaska Native Medical Center between January 1980 and July 1992.

STUDY DESIGN AND METHODS

Hard-copy transfusion records data were entered, and available databases were queried to identify deceased patients and the mailing address of those living. Patients were notified by letter of their HCV risk and encouraged to seek counseling and testing. Serum samples were screened for anti-HCV and HCV RNA, and program costs were estimated.

RESULTS

Overall, 3169 transfusion recipients were identified, with 1356 (43%) living and targeted for notification. Of 764 patients notified and screened by this program, 41 (5%) were anti-HCV-positive and 19 (2%) were HCV RNA-positive. There was a higher probability of detecting anti-HCV with each subsequent increase of a transfusion event. Among 298 lookback patients, 33 percent were unaware of having received a blood transfusion. The estimated cost per person sent notification was US$57 and to detect an anti-HCV-positive case it was US$3146.

CONCLUSION

This general transfusion lookback program successfully notified and screened patients at a reasonable cost. Further investigation would be helpful in determining the role these programs or other measures could play in promoting HCV screening in persons receiving transfusions before July 1992, especially among those who are unaware of their transfusion history.

Hepatitis C-virus (HCV) antibodies in patients after kidney transplantation

The hepatitis C-virus (HCV) is the main etiologic agent of posttransfusion hepatitis (PTH). Most patients depending on hemodialysis need transfusion of blood before kidney transplantation. Of 272 patients after kidney transplantation, 27 (10%) were found to be anti-HCV-ELISA-positive (HCV-Antibody-ELISA, Ortho Diagnostics). The antibodies could be neutralized by HCV C-100-3 antigen. Eight of 22 patients (36%) who had more than one kidney transplantation were classified anti-HCV positive [30% (8/27) of all anti-HCV positive patients]. The number of transfused blood units ranged from 0 to 99 BU. Receiving more than one kidney graft or the transfusion of more than 5 units of blood increased the risk for HCV infection 3.5 or 4.1 times, respectively, compared with one transplantation or less than 5 units of blood. No significant interactions were seen between these two variables. Of the anti-HCV positive patients, 48% were anti-HBc negative as well as HBs-antigen negative, 52% were anti-HBc positive.

Regional blood usage review: a quality assessment study from New Jersey hospitals

In 1986, the American Red Cross/New Jersey Blood Service (NJBS) conducted a blood utilization review of the use of red blood cells (RBCs), platelets, and fresh frozen plasma (FFP) in nine hospitals in the NJBS region. The director of NJBS analyzed the collected data and categorized the justification criteria for blood transfusion. Their study found that female patients and patients over 60 years of age are the largest users of blood products, the average number of RBC units used is three, and the most common indication for RBC use is hypovolemia due to surgery. There was a high degree of compliance with justified criteria of use for RBC transfusion, although platelet and FFP use and pretransfusion nursing documentation require improvement.